1,810nm wavelength has the ability to extend through skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage

2,810nm wavelength can help patients with severe depression and anxiety

3,NIR light is absorbed by cytochrome C oxidase in mitochondria

4,Increased blood flow, energy, neuroprotection and less inflammation

5,Treat stroke traumatic, neurodegenerative and psychiatric disease.

6,Quality, Much Better price

7, Easy to operate, suitable for home or clinic use

8, Supply treatment protocols free

9, Best after-sale service

10.The helmet also with the nasal laser applicator &ear laser applicator(by remote controller controlled) , thus it can enhance the treatment efficiency effectively.

11. We divided the brain into 12 regions, each regions we can adjust the power intensity, frequency data and time.

In an Alzheimer's disease (AD) rat model induced by A , photobiomodulation (PBM) using an 808 nm continuous-wave laser diode over 5 days provided protection against A -induced cellular toxicity and improved long-term spatial and object recognition memory. This PBM regimen also reduced hyperphosphorylated tau (PHF1) protein levels and neuronal apoptosis. These results align with other research where a 632.8 nm continuous-wave laser PBM decreased neuronal loss and dendritic atrophy in the APP/PS1 double-transgenic AD mouse model.



Anxiety and depressive-like behaviors, recognized as early indicators of AD, can potentially increase the risk of developing the disease. Early intervention in these behaviors is crucial, and PBM has been shown to alleviate depression and anxiety. Specifically, PBM with a continuous-wave laser attenuated anxious-depressive behaviors and safeguarded against neuronal damage and apoptosis in an AD rat model, highlighting PBM's preventive or decelerating effects on AD progression.



Numerous clinical trials have documented PBM's benefits in AD treatment. A study using an 810-nm, 10-Hz pulsed LED light source for PBM therapy on patients with moderate-to-severe cognitive impairment revealed significant cognitive function improvement and anxiety reduction after a 12-week treatment. Another trial using continuous-wave near-infrared PBM therapy reported better cerebral perfusion, enhanced resting-state functional connectivity, and notable improvements in cognitive and behaviOral functions.



Supporting these findings, a case report involved patients with cognitive decline and olfactory dysfunction undergoing a mix of continuous-wave red (635 nm), near-infrared light (810 nm), and 10-Hz pulsed near-infrared (810 nm) PBM therapy. Post-treatment, significant improvements were observed in the Montreal Cognitive Assessment and Working Memory Questionnaire scores.



Expanding Horizons with Non-Invasive Therapies

An increasing number of clinical trials are investigating non-invasive PBM therapies for AD. Notably, a phase II clinical trial on gamma entrainment therapies (GENUS) has shown promise. These therapies, using 40-Hz pulsed light or 40-Hz blue light combined with 40-Hz auditory stimulation, have demonstrated neuroprotective effects in AD mouse models. They improved cognitive deficits and facilitated amyloid plaque clearance by engaging neuronal and glial responses, enhancing synaptic function, reducing neuroinflammation, and mitigating DNA damage-associated cytotoxicity.



Overall, these findings advocate for the potential therapeutic application of PBM in ameliorating cognitive impairment and alleviating anxiety and depressive-like behaviors in Alzheimer's disease.

Clibeanna Te: